US FDA approves Pfizer's nasal spray for migraine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Equities close higher as softer jobs data quiets rate-hike expectations
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
FDA approves Pfizer's (PFE) migraine nasal spray
March 10, 2023 11:44 AM ESTPfizer (NYSE: PFE) shares edged higher despite the overall dip in equities in the early part of Friday's session after it announced the U.S. Food and Drug Administration (FDA) has approved its migraine nasal spray.
ZAVZPRET was shown to be "statistically... More
